Benefits
Joint comfort in knee trials
Results are mixed. A Cochrane review of 20 trials found less pain and better function mainly in trials of one manufacturer's glucosamine sulfate; trials of other preparations and the eight best-concealed trials showed no significant benefit. A 2024 comparison pooling 30 trials found that glucosamine alone did not reach a clinically meaningful pain reduction.
Glucosamine with chondroitin for knee comfort
In a 1,583-person US trial, neither glucosamine, chondroitin nor both together reduced knee pain significantly more than placebo overall; in an exploratory subgroup with moderate to severe pain, the combination helped more people. A 6-month trial without a placebo group saw pain scores fall by about half with glucosamine plus chondroitin.
Joint space over 2 years
In a 2-year Australian trial of 605 adults with knee pain, glucosamine sulfate plus chondroitin slightly slowed joint space narrowing on X-ray (by 0.10 mm), but neither supplement alone did, and no group had less pain than placebo. In a 2-year Dutch trial in hip osteoarthritis, glucosamine sulfate did not slow narrowing or ease pain.
Tolerability in trials
In a Cochrane review, the number of people reporting side effects was similar with glucosamine and placebo. In a large US trial, adverse events were mild, infrequent and evenly spread across groups.
Mechanism of action
Cartilage building block (proposed)
Glucosamine is a building block of glycosaminoglycans, which help give cartilage its structure, and supplements are proposed to support cartilage. Trials have not shown consistent effects on joint structure: a 2-year knee trial found a small effect only for the combination with chondroitin, and a 2-year hip trial found none.
Clinical trials
Multicenter, randomized, double-blind, placebo- and celecoxib-controlled trial; 1,583 adults with symptomatic knee osteoarthritis; glucosamine hydrochloride 1,500 mg/day, chondroitin sulfate 1,200 mg/day, both, celecoxib 200 mg/day or placebo for 24 weeks (Clegg et al. 2006, N Engl J Med)
1,583 adults with knee osteoarthritis (mean age 59, 64% women).
The primary outcome, a 20% drop in knee pain, was not significantly more common with glucosamine (3.9 percentage points above placebo, p = 0.30), chondroitin or the combination (6.5 points, p = 0.09). In an exploratory subgroup with moderate to severe pain, the combination helped more people than placebo (79.2% vs 54.3%). Adverse events were mild and evenly spread.
Double-blind, randomized, placebo-controlled trial; 605 adults aged 45 to 75 with chronic knee pain; glucosamine sulfate 1,500 mg, chondroitin sulfate 800 mg, both, or placebo once daily for 2 years (Fransen et al. 2015, Ann Rheum Dis)
605 adults with chronic knee pain and medial joint space narrowing.
The combination slightly reduced 2-year joint space narrowing versus placebo (0.10 mm), while neither supplement alone had a significant structural effect. Knee pain fell in all four groups with no significant difference between them.
Multicenter, randomized, double-blind non-inferiority trial without a placebo group; 606 adults with grade 2 to 3 knee osteoarthritis and moderate to severe pain; chondroitin sulfate 400 mg plus glucosamine hydrochloride 500 mg three times daily or celecoxib 200 mg daily for 6 months (Hochberg et al. 2016, Ann Rheum Dis)
606 adults with painful knee osteoarthritis in four European countries.
WOMAC pain fell by about 50% in both groups, meeting the non-inferiority margin. With no placebo arm, the trial cannot show how much of the change was due to the supplement. Adverse events were low in both groups.
Randomized, controlled trial in Dutch primary care; 222 adults with hip osteoarthritis; glucosamine sulfate 1,500 mg or placebo once daily for 2 years (Rozendaal et al. 2008, Ann Intern Med)
222 adults with hip osteoarthritis.
WOMAC pain and function over 24 months and joint space narrowing at 24 months did not differ from placebo. Only one sensitivity analysis, based on extreme assumptions about missing data, was consistent with an effect.
Systematic review and meta-analysis of 20 randomized trials with 2,570 patients (Towheed et al. 2005, Cochrane Database Syst Rev)
People with osteoarthritis, mostly of the knee.
Pooled across all trials, glucosamine improved pain and Lequesne function scores, but the eight trials with adequate allocation concealment showed no benefit, and trials of non-Rotta preparations showed no significant benefit. WOMAC pain, stiffness and function did not improve. Glucosamine was as safe as placebo.
Systematic review and network meta-analysis of 30 randomized trials with 5,265 patients (Sumsuzzman et al. 2024, J Clin Med)
Adults with knee osteoarthritis.
Only glucosamine combined with omega-3, with ibuprofen, or with chondroitin and MSM reduced pain beyond the minimum clinically important difference; no other option, including glucosamine alone, met that threshold.